Arca Biopharma (ABIO)

Arca Biopharma (ABIO) Income Statement


Arca Biopharma Income Statement

Last quarter (Q1 2023), Arca Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Arca Biopharma's net income was $-1.35M. See Arca Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
--$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
Gross Profit
Operating Expense
$ 6.02M$ -10.60M$ 19.34M$ 9.77M$ 5.81M$ 8.12M
Operating Income
$ -9.12M$ -10.60M$ -19.34M$ -9.77M$ -5.81M$ -8.12M
Net Non Operating Interest Income Expense
$ 1.12M$ 675.00K$ 13.00K$ 19.00K$ 165.00K$ 154.00K
Other Income Expense
$ -3.00K$ 5.00K----
Pretax Income
$ -8.00M$ -9.93M$ -19.32M$ -9.75M$ -5.65M$ -7.96M
Tax Provision
-$ -186.00K$ 0.00$ -9.00K$ -167.00K$ -31.00K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -8.00M$ -9.93M$ -19.32M$ -9.74M$ -5.48M$ -7.93M
Basic EPS
$ -1.00M$ -0.69$ -1.39$ -2.07$ -4.15$ -10.31
Diluted EPS
$ -0.55$ -0.69$ -1.39$ -2.07$ -4.15$ -10.31
Basic Average Shares
$ 57.64M$ 14.41M$ 13.90M$ 4.71M$ 1.32M$ 769.39K
Diluted Average Shares
$ 57.64M$ 14.41M$ 13.90M$ 4.71M$ 1.32M$ 769.39K
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 6.02M$ -10.60M$ 19.34M$ 9.77M$ 5.81M$ 8.12M
Net Income From Continuing And Discontinued Operation
$ -8.00M$ -9.93M$ -19.32M$ -9.74M$ -5.48M$ -7.93M
Normalized Income
$ -5.48M-$ -19.32M$ -9.74M$ -5.48M$ -7.93M
Interest Expense
--$ 0.00$ 9.00K$ 7.00K$ 8.00K
$ -9.12M$ -10.60M$ -19.32M$ -9.74M$ -5.64M$ -7.96M
$ -7.51M$ -10.49M$ -19.23M$ -9.64M$ -5.55M$ -7.93M
Currency in USD

Arca Biopharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis